Approximately NIS 70 million investment in national infrastructure for AI models based on biological data featuring TeraCyte Analytics
New Israel BioToken Factory Initiative (IBFI) Brings Together NVIDIA, Teva, Sheba Medical Center, Startups and Universities to Develop the Next Generation of Biological AI
The Israel Innovation Authority today announced a NIS 70 million investment, together with leading industry partners, in the establishment of the Israel BioToken Factory Initiative (IBFI), a new national research and development consortium that will develop a shared technological infrastructure for the next generation of artificial intelligence applications in biology, drug discovery, and personalized medicine.
The consortium will develop a common technology platform that will enable companies, researchers, and healthcare organizations to build the next generation of AI models based on biological data. Among the consortium’s partners are NVIDIA, Teva Pharmaceutical Industries, Sheba Medical Center, CytoReason, TeraCyte Analytics, and MeMed, alongside leading researchers from the Weizmann Institute of Science, the Technion – Israel Institute of Technology, and Ben-Gurion University of the Negev.
